Licensing exchange—Insights from the biopharmaceutical industry
نویسندگان
چکیده
منابع مشابه
R&D Licensing in the Biopharmaceutical Industry: How to Structure a Good Deal
Objectives. How to best structure an IP licensing agreement taking account of embedded optionalities and other terms negotiated between licensor and licensee via a case study involving a prototypical options-based business model (biotech industry). Methodology. Binomial lattice simulation. Findings. It shows how IP management practices would change depending on who pays for the development cost...
متن کاملCompetition and R&D Financing: Evidence from the Biopharmaceutical Industry∗
What is the interaction between competition, R&D investments, and the financing choices of R&D-intensive firms? Motivated by existing theories, we hypothesize that as competition increases, R&D-intensive firms will: (1) increase R&D investment relative to assets-in-place that support existing products; (2) carry more cash; and (3) maintain less net debt. We provide causal evidence supporting th...
متن کاملHow the biopharmaceutical industry uses molecular imaging.
How the Biopharmaceutical Industry Uses Molecular Imaging O ver the past decade, biomarkers have been recognized as a critical element needed to improve predictability and efficiency in the process of developing more effective, more affordable, and safer therapeutics for patients. Biomarkers can provide information critical to both internal decision making (e.g., establish presence of target, e...
متن کاملUniversity-Industry Collaboration in Biopharmaceutical Industry: The Italian Case
Abstract We investigate the determinants of University-Industry interactions in the biopharmaceutical in Italy, over the period 2004-2010. Because of the specificities of biopharmaceutical industry, we choose co-publishing as a proxy of University-Industry relations. By integrating different statistical sources, we construct a novel dataset of co-published articles containing measures of proxim...
متن کاملCapital Structure Decisions in the Biopharmaceutical Industry
In this paper we deal with the capital structure problem in the pharmaceutical industry that has recently changed its business model because of the biotechnology advent. We propose a set of hypotheses that explains the drivers of capital structure decision in this industry and then we test their validity over a sample of 50 biopharmaceutical firms. The obtained results show that pecking order t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of Research in Marketing
سال: 2008
ISSN: 0167-8116
DOI: 10.1016/j.ijresmar.2008.07.004